Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression

Bibliography

• Kessler RC, Chiu WT, Demler O, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007;29:409-16
   PubMed Web of Science ®Google Scholar
• Chang HJ, Lin HC, Lee HC, Risk of mortality among depressed younger patients: a five-year follow-up study. J Affect Disord 2009;113:255-62
   PubMed Web of Science ®Google Scholar
• Murphy JM, Burke JDJr, Monson RR, Mortality associated with depression: a forty-year perspective from the Stirling County Study. Soc Psychiatry Psychiatr Epidemiol 2008;43:594-601
   PubMed Web of Science ®Google Scholar
• Schulz R, Beach SR, Ives DG, Association between depression and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2000;160:1761-8
   PubMed Web of Science ®Google Scholar
• Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007;164:201-4
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, ; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Anderson IM, Ferrier IN, Baldwin RC, Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-96
   PubMed Web of Science ®Google Scholar
• Bauer M, Bschor T, Pfennig A, ; WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007;8:67-104
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Denberg TD, ; Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American college of physicians. Ann Intern Med 2008;149:725-33
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Gaynes BN, Hansen RA, Comparative benefits and harms of second-generation antidepressants: background paper for the American college of physicians. Ann Intern Med 2008;149:734-50
   PubMed Web of Science ®Google Scholar
• Turner EH, Matthews AM, Linardatos E, Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Entsuah R, Benattia I, Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Watanabe N, Omori IM, Nakagawa A, ; Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008;69:1404-15
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Thase ME, Fava M, Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217-27
   PubMed Web of Science ®Google Scholar
• Hedlund PB, Sutcliffe JG. The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder. Neurosci Lett 2007;414:247-51
   PubMed Web of Science ®Google Scholar
• Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 1997;322:147-53
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Starr KR, Langmead CJ, Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57
   PubMed Web of Science ®Google Scholar
• Celada P, Puig M, Amargós-Bosch M, The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252-65
   PubMed Web of Science ®Google Scholar
• Navinés R, Martín-Santos R, Gómez-Gil E, Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response. Psychoneuroendocrinology 2007;32:411-6
   PubMed Web of Science ®Google Scholar
• Rickels K, Athanasiou M, Robinson DS, Vilazodone, evidence for efficacy and tolerability in the treatment of major depressive disorder: a randomized, double-blind placebo-controlled trial. J Clin Psychiatry 2009;70:326-33
   PubMed Web of Science ®Google Scholar
• Rickels K, Athanasiou M, Reed C. Vilazodone, a novel dual acting antidepressant: current status, future promise and potential for individualized treatment of depression. Pers Med 2009;6:217-24
   PubMed Web of Science ®Google Scholar
• Adamec R, Bartoszyk GD, Burton P. Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol 2004;504:65-77
   PubMed Web of Science ®Google Scholar
• Roberts C, Hagan JJ, Bartoszyk GD, Kew JN. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus. Eur J Pharmacol 2005;517:59-63
   PubMed Web of Science ®Google Scholar
• Page ME, Cryan JF, Sullivan A, Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther 2002;302:1220-7
   PubMed Web of Science ®Google Scholar
• Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Cunningham L, Horrigan JP, Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry 2008;69:571-7
   PubMed Web of Science ®Google Scholar
• Gammans RE, Stringfellow JC, Hvizdos AJ, Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. a meta-analysis of eight randomized, controlled studies. Neuropsychobiology 1992;25:193-201
   PubMed Web of Science ®Google Scholar
• Robinson DS, Rickels K, Feighner J, Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10(3 Suppl):67S-76S
   PubMedGoogle Scholar
• Whale R, Terao T, Cowen P, Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol 2008; doi: 10.1177/0269881108097714
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Kasik KE, Stahl SM. Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response. Neuropsychopharmacology 2006;31:2274-80
   PubMed Web of Science ®Google Scholar
• Rabiner EA, Gunn RN, Wilkins MR, Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol 2000;27:509-13
   PubMed Web of Science ®Google Scholar
• Murck H, Frieboes RM, Antonijevic IA, Steiger A. Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology 2001;155:187-92
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Bühring KU, Dasenbrock J, Studies comparing in vivo: in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey and human using cryopreserved hepatocytes, microsomes and collagen gel-immobilized hepatocyte cultures. Drug Metab Dispos 2001;29:1042-50
   PubMed Web of Science ®Google Scholar
• Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006;367:153-67
   PubMed Web of Science ®Google Scholar
• Paddock S, Laje G, Charney D, Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007;164:1181-8
   PubMed Web of Science ®Google Scholar
• Perlis RH, Moorjani P, Fagerness J, Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D Study. Neuropsychopharmacology 2008;33:2810-9
   PubMed Web of Science ®Google Scholar
• Khan A, Kolts RL, Thase ME, Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004;161:2045-9
   PubMed Web of Science ®Google Scholar
• Khan A, Bhat A, Kolts R, Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? 2009. [Submitted]
   Google Scholar
• Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-7
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63:1217-23
   PubMed Web of Science ®Google Scholar